GlycoSyn seeks new customers for drug ingredient worth 20 times more than gold

Tue, 04 Nov 2014

By Fiona Rotherham Nov. 5 (BusinessDesk) - GlycoSyn is seeking new global customers for kifunensine, a key ingredient in the manufacture of a drug for the treatment of rare genetic disorders that's worth 20 times more than gold on a per-gram basis. The drug research, development, and manufacturing unit of Callaghan Innovation is a world leader in carbohydrate chemistry and has sold more than $16 million of clinical grade kifunensine to a US-based biotech company in the past seven years. It is now marketing the ingredient to other pharma t...

Not convinced yet?

Subscribe to our Daily News Update free newsletter.

The Economist
How attractively are shares now priced?
The Economist | Sun, 26 Jun 2022

What a key valuation measure says about buying the dip.

The $100 Club: A wine rich list
Bob Campbell MW | Sun, 26 Jun 2022

If you're a wine connoisseur, you're spoiled for choice. The number of high-flying wines on sale for more than $100 has tripled since 2013.

Property FREE
Money Answers: how much mortgage can I actually afford?
Frances Cook | Sat, 25 Jun 2022

This week, readers ask how they should decide as a family what they can afford in terms of buying a house – and just because you can, should you?

Investments to sustain the momentum of building in NZ

Classic Capital has opened its Land & Build fund to qualified wholesale and eligible investors.

High water marks: Watercare raises the tide on sustainability

The No.1 barrier to decarbonisation for NZ organisations is accurate measurement, says Microsoft’s Accelerating the Journey to Net Zero report.